Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
Qunlian Huang,1 Xiaoyan Zhong,1 Ye Yun,1 Bin Yu,2 Yilan Huang1 1Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, 2Department of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan Province, People’s Republic of China Object...
Enregistré dans:
Auteurs principaux: | Huang Q, Zhong X, Yun Y, Yu B, Huang Y |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2016
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/db5d6893455c4d9fb46afab643defdfb |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Clinical and Neurocognitive Predictors of Functional Outcome in Depressed Patients with Partial Response to Treatment: One Year Follow-Up Study
par: Castellano S, et autres
Publié: (2020) -
The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials
par: Li G, et autres
Publié: (2016) -
Pioglitazone could induce remission in major depression: a meta-analysis
par: Colle R, et autres
Publié: (2016) -
Elevated peripheral blood glutamate levels in major depressive disorder
par: Inoshita M, et autres
Publié: (2018) -
The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone
par: McIntyre RS
Publié: (2017)